International Anatolia Academic Online Journal Health Sciences
Yazarlar: Beyza Özçınar, Sibel OZKAN GURDAL, Gamze CITLAK, Atilla BOZDOGAN, Vahit OZMEN, Abdullah IGCI, Mahmut MUSLUMANOGLU
Konular:-
Anahtar Kelimeler:Breast cancer,Triple negative,Her2 positive,Survival,Local recurrence
Özet: Objectives:The aim of this study is to investigate the results of clinicopathological characterics of patients with Her 2 positive (Any ER, any PR status with Her2 +) and triple negative (ER-, PR-, Her2-) subgroups of breast cancer.Patients and Methods: From prospective database of 1822 patients, 133 triple negative patients and 160 Her 2 receptor positive patients’ data collected retrospectively. Clinical, histopathological characteristics (tumor size, tumor receptor status, axillary node involvement, histological grade, lymphovascular invasion, necrosis, tumor type), treatment modalities and survival rateswere recorded. One way ANOVA, chi square and Kaplan Meier tests were used for statistical analysis. P value of <0.05 was accepted as a significant.Results:When we compared the characteristics of both groups, lymphovascular invasion (p<0.001), higher grade (grade 3) (p=0.003), adjuvant chemotherapy (p<0.001) rates were significantly more in Her 2 positive subgroup. Micrometastasis at sentinel lymph node (p=0.009), local recurrence rate (p=0.032) were more significant in triple negative subgroup. Her 2 + patientstend to have more non sentinel lymph node metastasis (p<0.001). 5 years survival of Her 2 positive patients was 95.6%, triple negative patients was 92.0% (p=0.731). 5 years disease free survival rate of Her 2 patients was 85.5% and triple negative patients was 82.6% (p=0.689). Breast conserving surgery rate was more in triple negative group (p=0.008). Triple Ozcinaret al. negative group had much local recurrence than Her2 positive group, but this was notstatistically significant.Conclusion:Tumors with TN subgroup had poorer prognosis than counterparts of Her 2 + group in this study, but this is not significant statistically. Both subgroups have poorer survival than ER+, PR+ and Her2- subgroup of breast cancer patients according to international literature.